Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.

Equities

603168

CNE100001TG0

Pharmaceuticals

End-of-day quote Shanghai S.E. 03:30:00 08/05/2024 am IST 5-day change 1st Jan Change
8.99 CNY -1.10% Intraday chart for Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. +1.35% -32.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shapuaisi Pharma Gets China's Nod to Market Sodium Hyaluronate Eye Drops MT
Shapuaisi Pharma Gets Marketing Authorization for Moxifloxacin Hydrochloride Eye Drops MT
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shanghai Lechun Biotechnology Co., Ltd. sign a share transfer agreement to acquire a 14.5% stake in Advanced Sterile Solutions Biotechnology Co., Ltd. from Shanghai Changgeng Industrial Development Co., Ltd. and Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. for CNY 40.6 million. CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Taizhou Women and Children's Hospital Co., Ltd. announced that it expects to receive CNY 231.1828 million in funding from Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. agreed to acquire Qingdao Shikang Eye Hospital Co., Ltd. from Shanghai Fangzhi Medical Management Co., Ltd. for CNY 66.5 million CI
Zhejiang Shapuaisi Pharma Shareholder Boosts Stake Through $44 Million Deal MT
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. announced that it has received CNY 317.999993 million in funding from Shanghai Yanghe Investment Management Co., Ltd. and other investor. CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. announced that it expects to receive funding from Shanghai Yanghe Industrial Co., Ltd. CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Shanghai Tonghui Medical Management Co., Ltd. completed the acquisition of 5.43% stake in Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. from Chen Dekang. CI
Shanghai Tonghui Medical Management Co., Ltd. signed a share transfer agreement to acquire 5.43% stake in Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. from Chen Dekang for approximately CNY 400 million. CI
Zhejiang Shapuaisi Pharma's Shareholder to Sell 5.4% Stake for 396.5 Mln Yuan CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Jilin Yueshi Tianbo Pharmaceutical Co., Ltd. signed an agreement to acquire Shapuaisi Qiangshen Pharmaceutical Co., Ltd. from Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. for CNY 82 million. CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 599.999995 million in funding from Shanghai Yanghe Investment Management Co., Ltd. and another investor CI
Chart Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.
More charts
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. is a China-based company principally engaged in the production, research, development and sale of chemical medicine and Chinese patent drugs. The Company's chemical medicine products mainly include Shapuaisi Bendazac Lysine Eye Drops, infusion products and cefixime products. The Company's Chinese patent drugs include kidney tonifying and nerve soothing products, such as Sizi Tianjing Capsules and Compound Gaoshan Hongjingtian Solution. The Company distributes its products in domestic market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603168 Stock
  4. News Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.
  5. Zhejiang Shapuaisi Pharma Shareholder Boosts Stake Through $44 Million Deal
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW